Reliability of Quantitative Sensory Testing in Sickle Cell Disease
Quantitative sensory testing may facilitate objective evaluation of feelings of pain and function in patients with sickle cell disease.
Quantitative sensory testing may facilitate objective evaluation of feelings of pain and function in patients with sickle cell disease.
Mometasone usage was found to correlate with decreased levels of macrophage markers but not of asthma-related markers.
Infants with sickle cell disease who started hydroxyurea before 12 months of age had better long-term outcomes.
A set of diagnostic criteria for defining the types of acute pain observed in patients with sickle cell disease was formulated by a multi-institutional panel of experts.
The use of a less toxic conditioning regimen may establish bone marrow transplantation as a preferred therapeutic alternative for adults with sickle cell disease.
Novartis announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for crizanlizumab (SEG101) for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease.
Researchers assessed 266 pregnant women with and without sickle cell disease in Ghana to determine the effect of a multidisciplinary care strategy.
In addition to the 1000mg tablet, Siklos is also available in 100mg tablets.
Allogeneic hematopoietic cell transplantation was tolerated well by pediatric patients with sickle cell disease and transfusion-dependent thalassemia.
Investigators conducted a systematic review of 7083 studies to evaluate the association between sickle cell trait and any of 24 adverse clinical outcomes.